Thursday, November 28, 2019
A precision drug for prostate cancer may slow the disease’s spread
Related Article: https://www.google.com/amp/s/www.bbc.com/news/amp/health-49877843
Recently, researchers have discovered that a drug used to treat breast and ovarian cancers is also tied to certain genetic mutations that may help combat some of the most severe cases of prostate cancer.
Researchers tested the drug, called olaparib, in a randomized clinical trial of nearly 400 men with advanced prostate cancer and a mutation in one of several genes involved in repairing damaged DNA, such as and .
Overall in men given olaparib, the disease progressed more slowly compared with those on standard treatment drugs that deprive cancer cells of the male hormone testosterone. After a year, about 22 percent of men taking olaparib had no signs that their cancer was progressing, compared with 13.5 percent of men on the standard treatments, the researchers reported September 30 in Barcelona at the European Society of Medical Oncology meeting.
This was a very interesting article to read. Although it is too early to say how the drug will impact overall survival , this new treatment looks promising so far, potentially buying some patients a few more months